| Serial Number | 79340795 |
| Word Mark | BRC |
| Filing Date | Friday, February 25, 2022 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, July 9, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 9, 2024 |
| Goods and Services | Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease; none of the foregoing in the field of palliative care |
| Goods and Services | Pharmaceutical compounding services; advisory services relating to pharmaceuticals; pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care |
| Goods and Services | Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bicycletx Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Bicycletx Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, May 19, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, May 20, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, May 24, 2022 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, September 7, 2022 | ASSIGNED TO EXAMINER |
| Saturday, September 10, 2022 | NON-FINAL ACTION WRITTEN |
| Sunday, September 11, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, September 24, 2022 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Friday, October 28, 2022 | REFUSAL PROCESSED BY MPU |
| Friday, October 28, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, November 21, 2022 | REFUSAL PROCESSED BY IB |
| Wednesday, April 26, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, April 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 25, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Monday, May 22, 2023 | SUSPENSION LETTER WRITTEN |
| Monday, May 22, 2023 | LETTER OF SUSPENSION E-MAILED |
| Monday, May 22, 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Sunday, November 12, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Wednesday, October 25, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Friday, December 1, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, January 8, 2024 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Monday, January 29, 2024 | FINAL REFUSAL WRITTEN |
| Monday, January 29, 2024 | FINAL REFUSAL E-MAILED |
| Monday, January 29, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, May 29, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, May 29, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, May 29, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Saturday, June 1, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, June 19, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 9, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 9, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |